JP2010540508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540508A5 JP2010540508A5 JP2010526362A JP2010526362A JP2010540508A5 JP 2010540508 A5 JP2010540508 A5 JP 2010540508A5 JP 2010526362 A JP2010526362 A JP 2010526362A JP 2010526362 A JP2010526362 A JP 2010526362A JP 2010540508 A5 JP2010540508 A5 JP 2010540508A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- represent
- optionally substituted
- direct bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 78
- 229910052739 hydrogen Inorganic materials 0.000 claims 29
- 239000001257 hydrogen Substances 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000005843 halogen group Chemical group 0.000 claims 22
- 125000001424 substituent group Chemical group 0.000 claims 19
- 201000010099 disease Diseases 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 150000001408 amides Chemical class 0.000 claims 14
- 150000002148 esters Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 239000012453 solvate Substances 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 238000006243 chemical reaction Methods 0.000 claims 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 125000002947 alkylene group Chemical group 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000002671 adjuvant Substances 0.000 claims 7
- 239000003085 diluting agent Substances 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- -1 4-fluoro-1-naphthyl Chemical group 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- 206010062016 Immunosuppression Diseases 0.000 claims 3
- 208000009905 Neurofibromatoses Diseases 0.000 claims 3
- 102000042867 PIM family Human genes 0.000 claims 3
- 108091082273 PIM family Proteins 0.000 claims 3
- 208000031481 Pathologic Constriction Diseases 0.000 claims 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 230000001506 immunosuppresive effect Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 201000004931 neurofibromatosis Diseases 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 3
- 208000015768 polyposis Diseases 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 238000006722 reduction reaction Methods 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- 208000037804 stenosis Diseases 0.000 claims 3
- 230000036262 stenosis Effects 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 2
- 238000007254 oxidation reaction Methods 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 238000006268 reductive amination reaction Methods 0.000 claims 2
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims 2
- 150000003512 tertiary amines Chemical class 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 150000001340 alkali metals Chemical group 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000001302 tertiary amino group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 0 **c1c(*)nc(B2)[n]1N=C2*N* Chemical compound **c1c(*)nc(B2)[n]1N=C2*N* 0.000 description 5
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07381066 | 2007-09-27 | ||
| EP07381066.5 | 2007-09-27 | ||
| PCT/GB2008/003287 WO2009040552A2 (en) | 2007-09-27 | 2008-09-29 | Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540508A JP2010540508A (ja) | 2010-12-24 |
| JP2010540508A5 true JP2010540508A5 (Direct) | 2011-11-17 |
| JP5410431B2 JP5410431B2 (ja) | 2014-02-05 |
Family
ID=39092755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010526362A Expired - Fee Related JP5410431B2 (ja) | 2007-09-27 | 2008-09-29 | イミダゾロチアジアゾール類のプロテインキナーゼ阻害剤としての使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8563550B2 (Direct) |
| EP (1) | EP2193133B1 (Direct) |
| JP (1) | JP5410431B2 (Direct) |
| CN (1) | CN101878219B (Direct) |
| CY (1) | CY1116882T1 (Direct) |
| DK (1) | DK2193133T3 (Direct) |
| ES (1) | ES2548768T3 (Direct) |
| HR (1) | HRP20151128T1 (Direct) |
| HU (1) | HUE025976T2 (Direct) |
| PL (1) | PL2193133T3 (Direct) |
| PT (1) | PT2193133E (Direct) |
| SI (1) | SI2193133T1 (Direct) |
| WO (1) | WO2009040552A2 (Direct) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| JP5740076B2 (ja) | 2005-07-25 | 2015-06-24 | エマージェント・プロダクト・ディベロップメント・シアトル・エルエルシー | Ｃｄ３７特異的及びｃｄ２０特異的結合分子を用いたｂ細胞の減少 |
| NZ596865A (en) | 2006-06-12 | 2013-07-26 | Emergent Product Dev Seattle | Single-chain multivalent binding proteins with effector function |
| EP2193133B1 (en) | 2007-09-27 | 2015-08-19 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Imidazolothiadiazoles for use as protein kinase inhibitors |
| CN105198997B (zh) | 2008-04-11 | 2018-08-31 | 阿普拜佛研发有限责任公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
| US8389554B2 (en) * | 2008-07-29 | 2013-03-05 | MERCK Patent Gesellschaft mit beschränkter Haftung | Imidazothiadiazole derivatives |
| WO2010112874A1 (en) * | 2009-04-02 | 2010-10-07 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives |
| FR2945289A1 (fr) * | 2009-05-11 | 2010-11-12 | Sanofi Aventis | Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique |
| US20130029967A1 (en) | 2009-09-24 | 2013-01-31 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| WO2011101644A1 (en) | 2010-02-18 | 2011-08-25 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Triazolo [4, 5 - b] pyridin derivatives |
| WO2011121317A1 (en) | 2010-04-01 | 2011-10-06 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors |
| WO2011159726A2 (en) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| WO2012020215A1 (en) | 2010-08-09 | 2012-02-16 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors |
| WO2012020217A1 (en) | 2010-08-09 | 2012-02-16 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors |
| WO2012020227A1 (en) | 2010-08-11 | 2012-02-16 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
| EP2655362A1 (en) | 2010-12-22 | 2013-10-30 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| HRP20220319T1 (hr) | 2011-05-19 | 2022-05-13 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Makrociklički spojevi kao inhibitori protein kinaze |
| WO2013005041A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Tricyclic heterocyclic compounds as kinase inhibitors |
| WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
| WO2013004984A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
| EP2671885A1 (en) * | 2012-06-05 | 2013-12-11 | Ares Trading S.A. | Imidazo-oxadiazole and Imidazo-thiadiazole derivatives |
| EP2682395A1 (en) | 2012-07-04 | 2014-01-08 | Laboratorios Del. Dr. Esteve, S.A. | Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments |
| JP6483610B2 (ja) * | 2012-07-18 | 2019-03-13 | ユニバーシティ オブ ノートルダム デュ ラック | ５，５−ヘテロ芳香族抗感染症化合物 |
| CN108367004B (zh) | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | Cd3结合多肽 |
| KR102488323B1 (ko) | 2015-12-10 | 2023-01-12 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 또는 개선을 위한 조성물 |
| WO2017184520A1 (en) * | 2016-04-18 | 2017-10-26 | Vanderbilt University | Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists |
| JP7376471B2 (ja) | 2017-06-05 | 2023-11-08 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| BR112019027719A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
| KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| AU2019294482B2 (en) | 2018-06-27 | 2022-09-01 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
| SMT202400286T1 (it) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics Inc | Composti eterociclici ed eteroarilici per il trattamento della corea di huntington |
| TWI811428B (zh) | 2018-08-21 | 2023-08-11 | 日商杏林製藥股份有限公司 | 雙環雜芳香環衍生物 |
| PE20221318A1 (es) | 2019-10-21 | 2022-09-08 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| US20250042920A1 (en) * | 2021-11-29 | 2025-02-06 | Ocean University Of China | Imidazothiazole derivative, preparation method therefor, and application thereof |
| CN114195736B (zh) * | 2021-12-30 | 2023-08-04 | 浙江闰土染料有限公司 | 2-氨基-5-溴-1,3,4-噻二唑的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1464259A (en) * | 1975-10-03 | 1977-02-09 | Pfizer Ltd | Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents |
| NO811630L (no) | 1980-05-29 | 1981-11-30 | Bayer Ag | Imidazoazolalkensyreamider, nye mellomprodukter for deres fremstilling, deres fremstilling og deres anvendelse som legemiddel |
| DE3208437A1 (de) | 1982-03-09 | 1983-09-15 | Bayer Ag, 5090 Leverkusen | Imidazothiadiazolalkencarbonsaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln |
| IT1269176B (it) | 1994-01-11 | 1997-03-21 | Isagro Srl | Eterobicicli ad attivita' fungicida |
| AU7001396A (en) | 1995-09-22 | 1997-04-09 | Takeda Chemical Industries Ltd. | Triazole compounds, their production and use |
| BR0113139A (pt) | 2000-08-09 | 2003-06-24 | Agouron Pharma | Compostos, seus sais, formas multiméricas, pró-drogas ou metabólitos, composições farmacêuticas, método de tratamento de uma doença ou disfunção mediana através da inibição de cdk4 ou um complexo de cdk4/ciclina, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase e método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| CA2364985A1 (en) * | 2001-12-14 | 2003-06-14 | John W. Gillard | Imidazo(2,1-b)thiadiazole sulfonamides |
| AU2003297161B8 (en) | 2002-12-18 | 2011-03-31 | Vertex Pharmaceuticals Incorporated | Triazolopyridazines as protein kinases inhibitors |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| CA2527903A1 (en) * | 2003-06-13 | 2004-12-23 | Aegera Therapeutics, Inc. | Imidazo[2,1-b]-1,3,4-thiadiazole sulfoxides and sulfones |
| KR20060017645A (ko) * | 2003-06-13 | 2006-02-24 | 에게라 쎄라퓨틱스 인코포레이티드 | 아실화 및 비-아실화 이미다조[2,1-ｂ]-1, 3,4-티아디아졸-2-설폰아미드, 및 그 용도 |
| CA2610695A1 (en) * | 2005-06-01 | 2006-12-07 | Ucb Pharma, S.A. | 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| US7750000B2 (en) | 2005-09-02 | 2010-07-06 | Bayer Schering Pharma Ag | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments |
| EP1963329B1 (en) | 2005-11-30 | 2013-01-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| AU2007240082A1 (en) * | 2006-04-13 | 2007-10-25 | Aegera Therapeutics Inc. | Use of imidazo[2,1-b)]-1,3,4-thiadiazole-2-sulfonamide compounds to treat neuropathic pain |
| WO2007136730A2 (en) | 2006-05-21 | 2007-11-29 | Steven Allen Carlson | Systems and methods for hydrogen storage and generation |
| CN101037445A (zh) * | 2007-04-14 | 2007-09-19 | 西北师范大学 | 一种具有潜在生物活性的咪唑并[2，1－b]－1，3，4－噻二唑衍生物及其合成方法 |
| EP2155753A1 (en) | 2007-05-09 | 2010-02-24 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| JP2010528991A (ja) * | 2007-05-21 | 2010-08-26 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | 複素環式キナーゼ調節因子 |
| EP2193133B1 (en) | 2007-09-27 | 2015-08-19 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Imidazolothiadiazoles for use as protein kinase inhibitors |
| US8389554B2 (en) | 2008-07-29 | 2013-03-05 | MERCK Patent Gesellschaft mit beschränkter Haftung | Imidazothiadiazole derivatives |
-
2008
- 2008-09-29 EP EP08806437.3A patent/EP2193133B1/en active Active
- 2008-09-29 HR HRP20151128TT patent/HRP20151128T1/hr unknown
- 2008-09-29 PT PT88064373T patent/PT2193133E/pt unknown
- 2008-09-29 US US12/679,514 patent/US8563550B2/en not_active Expired - Fee Related
- 2008-09-29 PL PL08806437T patent/PL2193133T3/pl unknown
- 2008-09-29 DK DK08806437.3T patent/DK2193133T3/en active
- 2008-09-29 WO PCT/GB2008/003287 patent/WO2009040552A2/en not_active Ceased
- 2008-09-29 ES ES08806437.3T patent/ES2548768T3/es active Active
- 2008-09-29 HU HUE08806437A patent/HUE025976T2/en unknown
- 2008-09-29 JP JP2010526362A patent/JP5410431B2/ja not_active Expired - Fee Related
- 2008-09-29 SI SI200831527T patent/SI2193133T1/sl unknown
- 2008-09-29 CN CN200880118104.5A patent/CN101878219B/zh not_active Expired - Fee Related
-
2015
- 2015-11-03 CY CY20151100982T patent/CY1116882T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010540508A5 (Direct) | ||
| JP7641388B2 (ja) | 一連のピペリジン置換安息香酸系化合物及びその使用 | |
| JP2012524053A5 (Direct) | ||
| JP2020528889A5 (Direct) | ||
| JP2012522759A5 (Direct) | ||
| JP2014503574A5 (Direct) | ||
| JP2019510787A5 (Direct) | ||
| JP2014037426A5 (Direct) | ||
| RU2013156361A (ru) | Новые соединения | |
| HRP20160292T1 (hr) | Derivati 1-fenil-2-piridinilalkil-alkohola kao inhibitori fosfodiesteraze | |
| JPWO2020123827A5 (Direct) | ||
| JP2010506854A5 (Direct) | ||
| CA2661861A1 (en) | Heterocyclic fxr binding compounds | |
| ATE427949T1 (de) | 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung | |
| JP2012530713A5 (Direct) | ||
| JP4927098B2 (ja) | トリアルキルシリルベンジルアミノカルボキシインドール、インダゾールおよびインドリン、ならびにｃｅｔｐを介する障害の処置におけるそれらの使用 | |
| JP2011509309A5 (Direct) | ||
| JP2023508772A (ja) | Ｊａｋ阻害剤化合物及びその使用 | |
| JP2011510068A5 (Direct) | ||
| JP2011507929A5 (Direct) | ||
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2014520108A5 (Direct) | ||
| EP4149927A1 (en) | Enpp1 modulators and uses thereof | |
| WO2014129495A1 (ja) | 眼疾患処置薬 | |
| JPWO2020086732A5 (Direct) |